Pfizer’s Wager on Small Molecules, Summer IPO Flurries, Gilead’s Protein Degrader Play

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses
Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation
Amgen Antes Up for Otezla, AbbVie Does the Obvious & an siRNA Nails PCSK9
BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC